Stem Cell Innovations officially opened its european R&D facility in Leiden, the Netherlands
"Establishing a site in Europe is part of SCIZs strategy to become a global leading player in the rapidly evolving stem cell field", said CEO Dr. James Kelly. "We are now in a much better position to efficiently serve the growing European market for high quality drug discovery tools, including complex disease models that can be alternatives for animal testing. Moreover a site in the Netherlands will allow high-level interactions with EU leaders in cell-therapeutics, both from Industry and Academia".
The Company recently disclosed it has produced multiple lines of human pluripotent stem cells. These PC lines are able to maintain their undifferentiated state and normal chromosome complement. More importantly, the cells can be efficiently cultured in tissue culture plates without the use of feeder layers (xenofree).
The European site of SCI will be led by Dr. Helmuth van Es (CSO) and Ivo Piest (Senior Director Business & Corporate Development), both members of the Company's global management team.
Most read news
Topics
Organizations
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.